DSP-4Adrenergic neurotoxin CAS# 40616-75-9 |
- Valproic acid sodium salt (Sodium valproate)
Catalog No.:BCC2156
CAS No.:1069-66-5
- Scriptaid
Catalog No.:BCC2163
CAS No.:287383-59-9
- Panobinostat (LBH589)
Catalog No.:BCC3601
CAS No.:404950-80-7
- Belinostat (PXD101)
Catalog No.:BCC2153
CAS No.:414864-00-9
- Trichostatin A (TSA)
Catalog No.:BCC3605
CAS No.:58880-19-6
- ITF2357 (Givinostat)
Catalog No.:BCC2150
CAS No.:732302-99-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 40616-75-9 | SDF | Download SDF |
PubChem ID | 11957497 | Appearance | Powder |
Formula | C11H16BrCl2N | M.Wt | 313.06 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 125 mg/mL (399.28 mM; Need ultrasonic) | ||
Chemical Name | N-[(2-bromophenyl)methyl]-2-chloro-N-ethylethanamine;hydrochloride | ||
SMILES | CCN(CCCl)CC1=CC=CC=C1Br.Cl | ||
Standard InChIKey | NDDRNRRNYOULND-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C11H15BrClN.ClH/c1-2-14(8-7-13)9-10-5-3-4-6-11(10)12;/h3-6H,2,7-9H2,1H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Adrenergic neurotoxin. Displays neurotoxic effects on both peripheral and central noradrenergic neurons. |
DSP-4 Dilution Calculator
DSP-4 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1943 mL | 15.9714 mL | 31.9428 mL | 63.8855 mL | 79.8569 mL |
5 mM | 0.6389 mL | 3.1943 mL | 6.3886 mL | 12.7771 mL | 15.9714 mL |
10 mM | 0.3194 mL | 1.5971 mL | 3.1943 mL | 6.3886 mL | 7.9857 mL |
50 mM | 0.0639 mL | 0.3194 mL | 0.6389 mL | 1.2777 mL | 1.5971 mL |
100 mM | 0.0319 mL | 0.1597 mL | 0.3194 mL | 0.6389 mL | 0.7986 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- DMT-T
Catalog No.:BCC2843
CAS No.:40615-39-2
- DMT-Cl
Catalog No.:BCC2799
CAS No.:40615-36-9
- Cirazoline hydrochloride
Catalog No.:BCC6833
CAS No.:40600-13-3
- C34
Catalog No.:BCC5603
CAS No.:40592-88-9
- GW3965 HCl
Catalog No.:BCC3790
CAS No.:405911-17-3
- GW3965
Catalog No.:BCC1612
CAS No.:405911-09-3
- SB590885
Catalog No.:BCC4392
CAS No.:405554-55-4
- Cyclapolin 9
Catalog No.:BCC7571
CAS No.:40533-25-3
- Dadahol A
Catalog No.:BCN5457
CAS No.:405281-76-7
- NFPS
Catalog No.:BCC7484
CAS No.:405225-21-0
- Dovitinib (TKI-258, CHIR-258)
Catalog No.:BCC1169
CAS No.:405169-16-6
- CHIR-124
Catalog No.:BCC3750
CAS No.:405168-58-3
- ACHP
Catalog No.:BCC6223
CAS No.:406208-42-2
- IKK-2 inhibitor VIII
Catalog No.:BCC1642
CAS No.:406209-26-5
- Cornoside
Catalog No.:BCN7575
CAS No.:40661-45-8
- Taxifolin 3-O-beta-D-xylopyranoside
Catalog No.:BCN5458
CAS No.:40672-47-7
- O-Phospho-L-serine
Catalog No.:BCC6578
CAS No.:407-41-0
- Actinine
Catalog No.:BCN1744
CAS No.:407-64-7
- (-)-Bicuculline methiodide
Catalog No.:BCC7387
CAS No.:40709-69-1
- (+)-Nerolidol
Catalog No.:BCC8219
CAS No.:142-50-7
- CaCCinh-A01
Catalog No.:BCC6314
CAS No.:407587-33-1
- 1,7-Diepi-8,15-cedranediol
Catalog No.:BCN5460
CAS No.:40768-81-8
- FPL 55712
Catalog No.:BCC7310
CAS No.:40785-97-5
- PD 146176
Catalog No.:BCC7504
CAS No.:4079-26-9
DSP-4, a noradrenergic neurotoxin, produces sex-specific effects on pairing and courtship behavior in zebra finches.[Pubmed:23747610]
Behav Brain Res. 2013 Sep 1;252:164-75.
Norepinephrine (NE) is involved in a variety of behaviors across vertebrate species. In songbirds, NE is involved in singing and auditory perception, fundamental components of pair formation. Mechanisms of pairing remain poorly understood in avian species. NE is likely involved given its role in vocal communication and perception. Here, we tested the hypothesis that DSP-4 treatments (a noradrenergic neurotoxin that decreases NE) decreases singing in males, song perception in females and pairing in both sexes using a naturalistic paradigm. Females were tested for preferences of either control or DSP-4 males in a two-choice paradigm using live males. Both sexes were then tested for courtship and pair formation in aviaries. In the two-choice paradigm, control females showed a significant preference for control males over DSP-4 males, whereas DSP-4 females showed no such preference. In the aviary tests, DSP-4 males engaged in less courtship behavior, showed decreased pairing behaviors and increased pair latencies compared to control males. In females, DSP-4 treatments did not alter courtship or pairing behavior. Lower neural densities of noradrenergic fibers in song, auditory, and affiliative regions were observed in DSP-4 animals of both sexes. Furthermore, DBH-ir densities in these regions explained variations in courtship and pairing behaviors, as well as pairing status. Our results extend previous findings to naturalistic contexts, provide evidence that DBH-ir densities in specific regions correlate with pairing-related behaviors, and inform us of sex differences in the role of NE in pairing.
Noradrenergic-Dopaminergic Interactions Due to DSP-4-MPTP Neurotoxin Treatments: Iron Connection.[Pubmed:26718588]
Curr Top Behav Neurosci. 2016;29:73-86.
The investigations of noradrenergic lesions and dopaminergic lesions have established particular profiles of functional deficits and accompanying alterations of biomarkers in brain regions and circuits. In the present account, the focus of these lesions is directed toward the effects upon dopaminergic neurotransmission and expression that are associated with the movement disorders and psychosis-like behavior. In this context, it was established that noradrenergic denervation, through administration of the selective noradrenaline (NA) neurotoxin, DSP-4, should be performed prior to the depletion of dopamine (DA) with the selective neurotoxin, MPTP. Employing this regime, it was shown that (i) following DSP-4 (50 mg/kg) pretreatment of C57/Bl6 mice, both the functional and neurochemical (DA loss) effects of MPTP (2 x 20 and 2 x 40 mg/kg) were markedly exacerbated, and (ii) following postnatal iron (Fe(2+), 7.5 mg/kg, on postnatal days 19-12), pretreatment with DSP-4 followed by the lower 2 x 20 mg/kg MPTP dose induced even greater losses of motor behavior and striatal DA. As yet, the combination of NA-DA depletions, and even more so Fe(2+)-NA-DA depletion, has been considered to present a movement disorder aspect although studies exploring cognitive domains are lacking. With intrusion of iron overload into this formula, the likelihood of neuropsychiatric disorder, as well, unfolds.
Selective Lifelong Destruction of Brain Monoaminergic Nerves Through Perinatal DSP-4 Treatment.[Pubmed:26427851]
Curr Top Behav Neurosci. 2016;29:51-71.
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) is a highly selective neurotoxin for noradrenergic projections originating from the locus coeruleus (LC). The outcome of the systemic DSP-4 treatment of newborn rats is an alteration in postnatal development of the noradrenergic system, involving the permanent denervation of distal noradrenergic projection areas (neocortex, hippocampus, spinal cord), accompanied by noradrenergic hyperinnervation in regions proximal to the LC cell bodies (cerebellum, pons-medulla). DSP-4 is well tolerated by developing rats and does not increase the mortality rate. Permanent noradrenergic denervation in the cerebral cortex and spinal cord is present at all developmental stages, although this effect is more pronounced in rats treated with DSP-4 at an early age, i.e., up to postnatal day 5 (PND 5). Notably, regional hyperinnervation is a hallmark of neonatal DSP-4 treatment, which is not observed after either prenatal or adult DSP-4 application. In contrast to robust biochemical changes in the brain, DSP-4 treatment of newborn rats has a marginal effect on arousal and cognition functions assessed in adulthood, and these processes are critically influenced by the action of the noradrenergic neurotransmitter, norepinephrine (NE). Conversely, neonatal DSP-4 does not significantly affect 5-hydroxytryptamine (serotonin; 5-HT), dopamine (DA), gamma-aminobutyric acid (GABA), and histamine levels in brain. However, as a consequence of altering the functional efficacy of 5-HT1A, 5-HT1B, DA, and GABA receptors, these neurotransmitter systems are profoundly affected in adulthood. Thus, the noradrenergic lesion obtained with neonatal DSP-4 treatment represents a unique neurobiological technique for exploring the interplay between various neuronal phenotypes and examining the pathomechanism of neurodevelopmental disorders.
The selective neurotoxin DSP-4 impairs the noradrenergic projections from the locus coeruleus to the inferior colliculus in rats.[Pubmed:22754504]
Front Neural Circuits. 2012 Jun 28;6:41.
The inferior colliculus (IC) and the locus coeruleus (LC) are two midbrain nuclei that integrate multimodal information and play a major role in novelty detection to elicit an orienting response. Despite the reciprocal connections between these two structures, the projection pattern and target areas of the LC within the subdivisions of the rat IC are still unknown. Here, we used tract-tracing approaches combined with immunohistochemistry, densitometry, and confocal microscopy (CM) analysis to describe a projection from the LC to the IC. Biotinylated dextran amine (BDA) injections into the LC showed that the LC-IC projection is mainly ipsilateral (90%) and reaches, to a major extent, the dorsal and lateral part of the IC and the intercollicular commissure. Additionally, some LC fibers extend into the central nucleus of the IC. The neurochemical nature of this projection is noradrenergic, given that tyrosine hydroxylase (TH) and dopamine beta hydroxylase (DBH) colocalize with the BDA-labeled fibers from the LC. To determine the total field of the LC innervations in the IC, we destroyed the LC neurons and fibers using a highly selective neurotoxin, DSP-4, and then studied the distribution and density of TH- and DBH-immunolabeled axons in the IC. In the DSP-4 treated animals, the number of axonal fibers immunolabeled for TH and DBH were deeply decreased throughout the entire rostrocaudal extent of the IC and its subdivisions compared to controls. Our densitometry results showed that the IC receives up to 97% of its noradrenergic innervations from the LC neurons and only 3% from non-coeruleus neurons. Our results also indicate that TH immunoreactivity in the IC was less impaired than the immunoreactivity for DBH after DSP-4 administration. This is consistent with the existence of an important dopaminergic projection from the substantia nigra to the IC. In conclusion, our study demonstrates and quantifies the noradrenergic projection from the LC to the IC and its subdivisions. The re-examination of the TH and DBH immunoreactivity after DSP-4 treatment provides insights into the source, extent, and topographic distribution of the LC efferent network in the IC, and hence, contributes to our understanding of the role of the noradrenaline (NA) system in auditory processing.
Short and long term analysis of heart rate variations in spontaneously hypertensive rats: effects of DSP-4 administration.[Pubmed:16275495]
Biomed Pharmacother. 2005 Oct;59 Suppl 1:S203-8.
The purpose of this study was to investigate whether or not central noradrenergic neurons were involved in the time structure of circadian variation of heart rate (HR) in hypertension. We used spontaneously hypertensive rats (SHR(Izm)) and normotensive controls (Wistar Kyoto rats, WKY(Izm)). We selectively destroyed the noradrenergic neurons in the central nervous system (CNS) by administering noradrenergic neurotoxin, N-(2-chloroethy)-N-ethyl-2-bromobenzylamine (DSP4). Frequency domain measures of variation of HR (VHR) were obtained using the maximum entropy method. The 24-h time frame in VHR is usually dominant in both SHR(Izm) and WKY(Izm). Fourteen days after the administering of DSP4, the mean 24-h systolic arterial pressure (SAP) remained higher in SHR(Izm) than in WKY(Izm). After chemical lesion, ultradian rhythms (12-, 8-, 6-, and 4-h periods) in VHR became more remarkable in both SHR(Izm) and WKY(Izm) than before chemical lesion. Before chemical lesion, an inverse relationship existed between frequency and power spectral density in VHR, demonstrating 1/f(beta) characteristics. The slope of 1/f(beta) in VHR did not differ between SHR(Izm) and WKY(Izm). After the chemical lesion it did not also differ from that of each strain in control period (before lesion). Therefore, the noradrenergic neurons may not affect the time structure of HR in SHR(Izm) and WKY(Izm) for short-term time analysis. However, the intact noradrenergic neurons in CNS may be important to keep normal cardiac autonomic function in SHR(Izm) for long-term analysis.
DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats.[Pubmed:7370771]
Brain Res. 1980 Apr 28;188(2):513-23.
The pharmacological actions of the compound N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4) are compatible with a specific neurotoxic effect on both peripheral and central noradrenergic neurons. The systemic injection of DSP-4 to adult rats transiently alters sympathetic neurons in the periphery but in the central nervous system the compound determines a marked and prolonged reduction of noradrenaline (NA) levels in all brain regions studied. When DSP-4 was injected systemically to rats at birth in doses ranging from 6.25 to 100 micrograms/g, no changes were found in peripheral sympathetic neurons 40 days later. On the contrary, in the same conditions and in relation to the dose injected, there were marked and persistent changes in the levels of NA in different regions of the brain. In the cerebral cortex and the spinal cord, the neonatal injection of SDP-4 produced a marked and long-lasting depletion of NA levels, similar to that observed after injection of the compound to adult rats. These changes were accompanied by a moderate increase in brain stem NA and a marked elevation of the amine in the cerebellum. These changes, different from the depletion observed in both regions when the compound was given to adult rats, are however similar to those observed after the neonatal injection of the neurotoxic compounds 6-hydroxydopamine or its precursor amino acid, 6-hydroxydopa. This indicates that probably central noradrenergic neurons respond in the same manner after different chemical injuries. DSP-4 crosses the placental barrier because when it was given to pregnant rats at the end of gestation, long-term changes were found in brain NA levels in their offspring, similar to those produced by the neonatal administration of the compound. This new neurotoxic compound provides a very useful tool for the study of noradrenergic neurons both in adult animals and during ontogenesis.